Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers
Van K. Morris(The University of Texas MD Anderson Cancer Center), Michael Frumovitz(The University of Texas MD Anderson Cancer Center), Aaron Shafer(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Ming Guo(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), David Vining(The University of Texas MD Anderson Cancer Center), Ryan Huey(The University of Texas MD Anderson Cancer Center), Curtis A. Pettaway(The University of Texas MD Anderson Cancer Center), Michaela Onstad Grinsfelder(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Solly George(The University of Texas MD Anderson Cancer Center), Benny Johnson(The University of Texas MD Anderson Cancer Center)
Cited by 29
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
|Journal of Clinical Oncology|2022|580
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
|Journal of Clinical Oncology|2020|391